KRAS exon 2 mutation	Colorectal Cancer	KRAS exon 2 mutation	Colorectal Cancer	bevacizumab Sensitive: C2 – Inclusion Criteria bevacizumab Sensitive : C2	bevacizumab Sensitive: C2 – Inclusion Criteria bevacizumab Sensitive : C2
KRAS exon 2 mutation	Pancreatic Cancer	KRAS exon 2 mutation	Pancreatic Cancer	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3
KRAS exon 2 mutation	Colorectal Cancer	KRAS exon 2 mutation	Colorectal Cancer	panitumumab Resistant: C3 – Early Trials panitumumab Resistant : C3	panitumumab Resistant: C3 – Early Trials panitumumab Resistant : C3
KRAS exon 2 mutation	Non Small Cell Lung Cancer	KRAS exon 2 mutation	Non Small Cell Lung Cancer	gefitinib Resistant: C3 – Early Trials gefitinib Resistant : C3	gefitinib Resistant: C3 – Early Trials gefitinib Resistant : C3
KRAS exon 2 mutation	Colorectal Cancer	KRAS exon 2 mutation	Colorectal Cancer	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
KRAS exon 2 mutation	Colorectal Cancer	KRAS exon 2 mutation	Colorectal Cancer	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3
KRAS exon 2 mutation	Non Small Cell Lung Cancer	KRAS exon 2 mutation	Non Small Cell Lung Cancer	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3

KRAS exon 2 mutation

Associations